We have shown that CXCR5+CD8+T cells with high PD-1 expression intensely presented in the TCGA classification the MSI and EBV subtypes, and in the ACRG classification MSI subtype of GC, which might partially explain the underlining mechanism of superior response to anti-PD-1 therapy in MSI-high and EBV-positive GC. The gene discussed is CXCR5; the disease is gastric cancer.